SCHEMBL7741775

SCHEMBL7741775

CN(C)CCOc1nn(C)c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 2/20 0.70
CYP1A2 P05177 2/20 0.56
CYP2D6 P10635 2/20 0.56
KDM4E B2RXH2 2/20 0.56
GUCY1B2 O75343 1/20 0.56
CHRM2 P08172 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
CHRM1 P11229 1/20 0.56
DRD1 P21728 1/20 0.56
SLC6A2 P23975 1/20 0.56
SLC6A4 P31645 1/20 0.56
GUCY1A2 P33402 1/20 0.56
ADRA1A P35348 1/20 0.56
OPRM1 P35372 1/20 0.56
DRD3 P35462 1/20 0.56
SLC6A3 Q01959 1/20 0.56
GUCY1A1 Q02108 1/20 0.56
GUCY1B1 Q02153 1/20 0.56
KCNH2 Q12809 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7120033 0.93 CYP2D6 (0.66) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL13481257 0.83 CNR2 (0.56) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL17571535 0.82 KAT2B (1.00) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL9917397 0.79 DRD1 (0.88) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL8013419 0.78 HRH3 (0.74) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL9917492 0.76 ADRA1A (0.60) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL8007454 0.74 HRH3 (0.69) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
SCHEMBL7737863 0.73 CNR1 (0.51) CYP1A2KDM4ECNR2CNR1HTT
SCHEMBL7998369 0.72 CYP2D6 (0.59) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2
Benzydamine SCHEMBL26172 0.72 HRH3 (1.00) KAT2BCYP1A2CYP2D6KDM4EGUCY1B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES COMBINATORX (SINGAPORE) PTE. LTD. (SG) 2010-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009970-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES HTR1A, HTR3B, HTR3A KAT2B 3789/4885CYP1A2 588/4885CYP2D6 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.